DifGen Acquires Pharma Assets In South Florida
DifGen Pharmaceuticals LLC (“DifGen”) today announced the successful acquisition of the manufacturing and operating assets of a South Florida transdermal drug delivery business that DifGen acquired in April of 2023.
With the all cash transaction, DifGen acquires the manufacturing and operating assets of Aveva Drug Delivery Systems in South Florida.
Miramar-based Aveva is a global leader in the transdermal drug delivery arena. Aveva produces proprietary and generic transdermal drug delivery systems that help patients with smoking cessation, pain management, cardiovascular disease, and hypertension among other quality of life issues.
Transdermal patch manufacturing is a highly specialized and complex manufacturing process that involves four steps to advance developed formulas from the mixing phase to the packaging phase.
DifGen Expanding Florida Pharma Portfolio
With today’s acquisition announcement, DifGen has more than doubled the size of its pharmaceutical manufacturing footprint in the state of Florida.
Aveva’s 165,000-square-foot inhalation and respiratory dosage manufacturing facility was the focus of today’s press release which described DifGen’s new asset as “a state-of the art manufacturing capability to handle solutions/ suspension/ emulsions through blow-fill-seal, form fill seal technology and traditional filling of liquid and semi-solid products in a variety of dosage forms including stick packs and unit-dose cups.
Five months after DifGen’s April 2023 acquisition of Aveva Drug Delivery Systems, the company announced the completion of the U.S. FDA audit of its first South Florida manufacturing facility.
The company press release puts the new acquisition in context:
“Our acquisition of Aveva Drug Delivery Systems in April of 2023 coupled with this transaction has positioned us to be one of the largest pharmaceutical drug product manufacturers in the state of Florida with a footprint of over 400,000 square feet spread across the Fort Lauderdale region and a combined annual capacity of close to two billion finished dosage units.”
DifGen Relocating Corporate Headquarters to Florida
In addition to the Aveva asset acquisition, DifGen also announced that it will be relocating its corporate headquarters from New Jersey to a state-of-the-art, 40,000-square-foot facility in Miramar, Florida as of April 1, 2024.
The company currently operates dual headquarters in Hyderabad, India and Princeton, New Jersey.
Contact CII Today
If you own an established healthcare or manufacturing business and would like to get a better understanding of the current market value of your company and important steps you can take today to maximize that value, get in touch with a CII business advisor today.